Taken together, these results and related clinical studies define in detail the mechanisms underlying the destabilization of the NUMB-p53 tumor suppressor complex and lay the groundwork for novel therapeutic strategies designed to restore the function of this complex in tumor-initiating cells, leading to improved clinical outcomes in patients with HCC of several different etiological origins. This evidence concerns the gene TP53 and hepatocellular carcinoma.